MoonLake Immunotherapeutics
MLTX
MLTX
43 hedge funds and large institutions have $843M invested in MoonLake Immunotherapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
43
Holders Change
+10
Holders Change %
+30.3%
% of All Funds
0.69%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
21
Increased
11
Reduced
6
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$35.7M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$17.7M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.2M |
| 5 |
JPMorgan Chase & Co
New York
|
+$5.53M |
Top Sellers
| 1 |
BlackRock
New York
|
-$13.4M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$10.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$7.79M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$4M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.15M |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
MWM
51
Meridian Wealth Management
Lexington,
Kentucky
| – | -$154K | -15,000 | Closed |
|
|
VF
52
Virtu Financial
New York
| – | -$151K | -14,395 | Closed |
|
53
Two Sigma Investments
New York
| – | -$130K | -12,385 | Closed |
|
54
Goldman Sachs
New York
| – | -$106K | -10,110 | Closed |
|